Iovance Biotherapeutics Inc (IOVA)

Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company listed on NASDAQ under the ticker IOVA. The company focuses on cell therapies based on autologous tumor infiltrating lymphocytes, with activity in metastatic melanoma and other solid tumor cancers in the U.S. and abroad. Its marketed products include Amtagvi, an individualized T cell therapy for adults with previously treated advanced, unresectable, or metastatic melanoma, and Proleukin, an interleukin-2 product used in metastatic melanoma and metastatic renal cell carcinoma. Iovance also continues to develop a pipeline that includes lifileucel and several other programs across melanoma, cervical cancer, NSCLC, endometrial cancer, HNSCC, and certain blood cancers. The company has collaboration and licensing agreements with several organizations, including the NIH, NCI, Cellectis, Novartis, and Boehringer Ingelheim. Formerly known as Lion Biotechnologies, it adopted its current name in 2017 and is headquartered in San Carlos, California.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.